PeptideGlobal

Mazdutide and ecnoglutide join the China insurance list for type 2 diabetes from January

China will reimburse Innovent mazdutide and ecnoglutide for type 2 diabetes from 1 January, joining Ozempic and Mounjaro on the national list. Weight loss use stays uncovered and the negotiated prices were not disclosed.

Illustration for the story: Mazdutide and ecnoglutide join the China insurance list for type 2 diabetes from January

Illustration by Peptide Global, not a picture of the place in the story.

The short of itChina will reimburse the GLP-1 drugs mazdutide and ecnoglutide for type 2 diabetes from 1 January, adding them to Ozempic, Mounjaro and efsubaglutide alfa on the national list.

Two more GLP-1 drugs will join the China insurance list on 1 January for adults with type 2 diabetes. China's National Healthcare Security Administration said on 14 November that ecnoglutide, which Reuters attributes to Pfizer, and mazdutide from Innovent Biologics will be covered by the state scheme, according to a Reuters report carried by AsiaOne. They join a reimbursed GLP-1 group that already includes Novo Nordisk's Ozempic, Eli Lilly's Mounjaro and Innogen's efsubaglutide alfa. Weight loss use is not covered, and the negotiated prices were not published.

What the administration decided

The decision closes a process that ran through most of 2026. In late June both drugs passed the preliminary review for possible inclusion in the basic medical insurance drug catalogue, Reuters reported at the time, and Innovent shares rose about 7 percent on that news. The final step was a price negotiation with the administration, and its results were expected before the end of the year, an HSBC Qianhai Securities analyst told Reuters then. A drug whose talks fail is not reimbursed the following year. Both GLP-1 drugs cleared that stage, and coverage begins on 1 January. The administration added other medicines in the same round, among them two Eli Lilly treatments for ulcerative colitis and Crohn's disease and a CAR-T cancer therapy from JW Therapeutics.

That CAR-T product is the first of its kind on the list, the report said, which shows how far the reimbursement round reached this year. For the diabetes market the main point is narrower. The China insurance list now holds a wider set of GLP-1 receptor agonists for type 2 diabetes, including two newer Chinese-market entrants, which gives hospitals and patients more covered choices and gives payers more leverage over price. The scope matters as well. When the drugs passed the preliminary review, an Innovent spokesperson told Reuters that only diabetes treatment could be considered for insurance coverage in China, so the listing does not extend to chronic weight management, even though both molecules also hold weight management approvals from the national drug regulator.

How the China insurance list works for GLP 1 drugs

Listing in the national reimbursement drug list lets public hospitals across the country prescribe a medicine under the state scheme, which in a country of 1.4 billion people opens a far bigger patient pool. The trade-off is price. Reuters noted that the gain in volume from listing often comes with lower prices, because companies accept cuts in the negotiation to win coverage. The administration did not disclose the agreed prices for ecnoglutide or mazdutide, and neither company had put a figure in public at the time of the report. China also has the largest number of adults with diabetes in the world, according to an International Diabetes Federation estimate cited by Reuters, which makes diabetes coverage a large prize even without obesity.

Listing in the national reimbursement drug list lets public hospitals across the country prescribe a medicine under the state scheme, which in a country of 1.4 billion people opens a far bigger patient pool.

The order of entry tells the competitive story. Ozempic joined the list in 2022, according to Reuters. Mounjaro and efsubaglutide alfa, a GLP-1 drug from the Chinese developer Guangzhou Innogen Pharmaceutical, were added for type 2 diabetes from this year. Ecnoglutide and mazdutide follow from January. Each new listing gives doctors in public hospitals another reimbursed option and puts more pressure on the price of the brands already there. Novo Nordisk feels this most. Reuters reported that Ozempic pen sales in greater China, which covers the mainland, Taiwan and Hong Kong and is Novo's largest market after the United States, slipped 7 percent in 2025 to about 5.4 billion Danish crowns.

GLP-1 drugCompanyCovered for type 2 diabetes fromNote
Ozempic (semaglutide)Novo Nordisk2022Semaglutide brand from Denmark
Mounjaro (tirzepatide)Eli Lilly2026Dual GIP and GLP-1 agonist
Efsubaglutide alfaGuangzhou Innogen Pharmaceutical2026Chinese developer
MazdutideInnovent Biologics1 January 2027Dual glucagon and GLP-1 agonist
EcnoglutidePfizer, per Reuters1 January 2027Price not disclosed

Mazdutide and ecnoglutide in brief

Mazdutide acts on two receptors, glucagon and GLP-1, and Innovent describes it as the first drug of that kind approved for blood sugar control in adults with type 2 diabetes. The company announced that approval in September 2025, after earlier clearance for chronic weight management, and based it on two Phase 3 trials in Chinese patients. DREAMS-1 compared mazdutide alone with placebo, and DREAMS-2 compared it with dulaglutide in people already taking oral diabetes drugs, where blood sugar control was similar and weight loss larger on mazdutide, according to Innovent. The new coverage applies to the diabetes use only, which is the part of its label that payers agreed to fund through the national negotiation, while its weight management use stays self-pay.

Ecnoglutide is a GLP-1 receptor agonist approved in China for both type 2 diabetes and weight management, Reuters reported in June, and the agency names Pfizer as the company behind it in its coverage of the listing. Neither Pfizer nor Innovent had published the negotiated price at the time of the report, so it is not yet clear how far either drug was discounted to win a place. The listing also arrives as more Chinese makers prepare copies of semaglutide, held back by data protection until 2027 according to the semaglutide patent expiry map published earlier on this site. That wave would add generic pressure on top of the new branded competition.

What to watch on the China insurance list next

The first question is price. Once the new list takes effect, hospital purchasing data and provincial tender prices will show where ecnoglutide and mazdutide sit against Ozempic and Mounjaro, and whether the older brands respond. The second is uptake: listing removes a cost barrier, but each hospital still decides what to stock, so coverage on paper and use on the ward can differ for some time. The third is obesity. Weight management remains outside the China insurance list, and nothing in the 14 November decision changes that, so the large self-pay obesity market stays a separate fight in which companies set their own retail prices.

That obesity fight is already crowded. Chinese regulators are reviewing new filings, including a United Laboratories semaglutide filing for weight management, and China leads the regional pipeline of new obesity drugs. Readers who want the original wire report can find it on AsiaOne. For Novo Nordisk, which has relied on China as its second market, the combination of more reimbursed rivals, price talks and coming semaglutide copies adds to the pressure it already faces in the country. Lilly, Innovent and Pfizer have not said what sales they expect from the listing. Any future reimbursement for weight loss would need a fresh decision by the administration in a later round, and no timetable for that has been given.

Conclusion

Ecnoglutide and mazdutide join the China insurance list for type 2 diabetes on 1 January, widening the reimbursed GLP-1 group. The decision widens covered choices for diabetes patients and adds price pressure on Ozempic and Mounjaro, but weight loss use stays outside state coverage and the agreed prices remain undisclosed. Watch hospital tender prices, formulary uptake and the coming semaglutide copies in 2027.

Why it matters in China

National listing brings state reimbursement in public hospitals across China, which opens a large diabetes market and usually comes with a negotiated price cut. China is Novo Nordisk's second market and Ozempic sales there already fell in 2025.

What to watch

Hospital tender prices and uptake after 1 January, any response from Novo and Lilly, and whether weight management ever enters coverage.

Sources

  1. AsiaOne (Reuters): Pfizer, Innovent GLP-1 drugs added to China national insurance for diabetes
  2. Reuters via SRN News: Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review
  3. Innovent Biologics: Mazdutide approved by China NMPA for glycemic control in adults with type 2 diabetes

Spotted a wrong figure? Tell the desk; we fix errors under our corrections policy.

Peptide Global reports news about medicines and markets. Nothing here is medical or investment advice.